Lehigh Valley Health Network LVHN Scholarly Works

USF-LVHN SELECT

Understanding Anticoagulation Decisions in Atrial Fibrillation

John Cassel USF MCOM- LVHN Campus, John.Cassel@lvhn.org

Zhe Chen MD Lehigh Valley Health Network, zhe.chen@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/select-program

Part of the Medical Education Commons Let us know how access to this document benefits you

Published In/Presented At

Cassel, J. Chen, Z. (2019, March). *Understanding Anticoagulation Decisions in Atrial Fibrillation*. Poster Presented at: 2019 SELECT Capstone Posters and Presentations Day. Kasych Family Pavilon, Lehigh Valley Health Network, Allentown, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Understanding Anticoagulation Decisions in Atrial Fibrillation

John Cassel and Zhe Chen, M.D.

Lehigh Valley Health Network, Allentown, Pennsylvania



- uncoordinated beating of the atria¹
- AF disrupts cardiac blood flow, leading to the formation of thrombi that can then embolize, occluding cerebral blood flow²
- Untreated AF confers a fivefold increased risk of ischemic stroke³
- Treatment with anticoagulant medication reduces stroke risk; but increases bleeding risk^{4,5}
- Evidence-based guidelines exist to inform treatment decisions⁵.
- Only a fraction of eligible patients receive appropriate treatment in accordance with guidelines⁶

Problem Statement

The purpose of the present study is to assess, via review of physician-authored medical documentation, the reasons for prescriber avoidance of anticoagulation in patients with histories of both atrial fibrillation and stroke, and the clinical characteristics of these patients.

- Mean age of 81 years _
- 54% female

Patient Characteristics





Table 1: Patient Characteristics - Comorbidities of patient population **CKD:** Chronic Kidney Disease, **CHF:** Congestive Heart Failure, **ICH:** Intracerebral hemorrhage, SDH: Subdural hematoma, SAH: Subarachnoid hemorrhage

Reasons for Withholding OAC



- Inconsistent with current guidelines
- Modifiable risk factors
- Targets for physician- and patientdirected educational interventions
- Physicians have legitimate concerns and are accurately identifying patients at higher risk of bleeding
 - Increased use of shared decision making may assist proper navigation of risks / benefits of OAC
- Low usage rate of left atrial appendage occlusion surgery

Methods

Retrospective chart review of current LVHN patients

Inclusion criteria:

- History of atrial fibrillation
 - ICD-10: I48.0 I48.4, I48.9
 - Documented diagnostic evidence of AF
- History of stroke
 - ICD-10: I63.0 I63.9




Table 2: Reasons for Withholding OAC Medication. LAA: Left atrial appendage, Declined: Patient or caregiver declined treatment, Comfort measures: End-of-life or hospice care, AF due to another medical...: AF due to specific time-limited or treatable condition





Table 3: Risk Stratification

Compares CHA₂DS₂-VASc and HAS-BLED scores of patients deemed bleed risks, fall risks, and those who declined treatment with the cohort as a whole.



Conclusions

- Both OAC treatment and withholding carry the potential for catastrophic outcomes
- The gravity of this decision requires special attention to patient education and involvement in the decisionmaking process, including:
 - Shared-decision making tools
 - Visual aids for patient education
 - Usage of composite risk / benefit, "Net clinical benefit," measures in both physician and patient-directed education

REFERENCES

1. CDC. Atrial Fibrillation Fact Sheet. Division for Heart Disease and Stroke Prevention.

- **Exclusion criteria:**
 - Currently prescribed oral anticoagulant medication (OAC)
 - Less than one month of documented clinical history
 - Greater than twelve months since last documented clinical encounter




Table 4: Health System-related cohort data

Echocardiogram: Percentage of patients receiving echocardiogram within 6 months of AF diagnosis, Medication Bleed Risk: Percentage of patients on medications that increase bleed risk, **PCP Follow-up**: Percentage of patients who follow-up with a primary care provider (PCP) following AF diagnosis, Cardiology Follow-up: Percentage of patients seen by outpatient cardiology following AF diagnosis Lost to Follow-up: Percentage of patients with no documented clinical encounters for 60 days following their last encounter

https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. Published 2017. Accessed February 10, 2018.

- Hankey GJ. Stroke. Lancet. 2017;389(10069):641-654. 2.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561-1564.
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 5. management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. JAm Coll Cardiol. 2014;64(21):e1-76.
- Hess PL, Mirro MJ, Diener H-C, et al. Addressing barriers to optimal oral 6. anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J. 2014;168(3):239-247.e1.

© 2018 Lehigh Valley Health Network

Scholarly Excellence. Leadership Experiences. Collaborative Training.

Experiences for a lifetime. A network for life."



